Could a gene flaw weaken immunity in Alpha-1 patients?

NCT ID NCT07135427

Recruiting now Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to understand why some people with alpha-1 antitrypsin deficiency (AATD) get more respiratory infections. Researchers will compare immune responses to a pneumonia vaccine (PCV20) in 30 adults who carry one abnormal copy of the SERPINA1 gene. Half have had frequent COPD flare-ups, half have not. The goal is to see if nearby genetic variations affect immune function and infection risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 20-valent pneumococcal conjugate vaccine (PCV20)
What this could lead to: If successful, this study could help identify which patients with alpha-1 antitrypsin deficiency are at higher risk for infections and may benefit from tailored vaccination strategies.
What could go wrong: This is a small, early-stage observational study with only 30 participants, so results may not apply to everyone. It is designed to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agammaglobulinemia alpha 1-antitrypsin deficiency chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA 1-ANTITRYPSIN ANTIBODY DEFICIENCY COPD

Contacts and locations

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.